RL
Therapeutic Areas
ArriVent Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Firmonertinib | 1L NSCLC with EGFR Exon 20 Insertion Mutations | Phase 3 |
| Firmonertinib + SHP2 inhibitor | 2L+ NSCLC with EGFR Classical Mutations | Phase 1 |
| ARR-217 | Gastrointestinal (GI) Tumors | Preclinical |
| ARR-002 | Solid Tumors | Discovery |
| ARR-421 | Solid Tumors | Discovery |
| ARR-173 | Solid Tumors | Discovery |
Leadership Team at ArriVent Biopharma
Z(
Zhengbin (Bing) Yao, PhD
Chief Executive Officer, Chairman, Co-founder
SL
Stuart Lutzker, MD, PhD
President, Head of Research & Development, Co-founder
WK
Winston Kung, MBA
Chief Financial Officer
YW
Yang Wang, PhD
Chief Technology Officer
JK
James Kastenmayer, PhD, JD
General Counsel
BR
Brent Rice
Chief Commercial Officer